Loading…
This entity appears on both sides of lobbying disclosures. The firm tab shows registrant-reported income; the client tab shows client-reported lobbying spend. Contract awards are separate and are not included here.
Lobbying Spend
$38.2M
Filings
377
Firms Hired
10
Active Period
2008–2026
Client-reported lobbying expenses on LDA filings
Lobbying firms retained by this client; amounts are client-reported expenses when available
Government entities explicitly identified as targets in LDA filings
Most frequently reported lobbying issues
Bill numbers found in source-reported LDA specific issue text; broad topic matches are excluded
Access to innovative non-opioid medicines; Alternatives to PAIN, H.R. 1227; Alternatives to PAIN, S. 475.
Client expense: — · Firm income: $50,000
Matched citations: H.R. 1227
Access to innovative non-opioid medicines; Alternatives to PAIN, H.R. 1227; Alternatives to PAIN, S. 475.
Client expense: — · Firm income: $50,000
Matched citations: S. 475
Issues related to pain management, including S.475/H.R. 1227 - Alternatives to PAIN Act. Issues related to prescription drug value, including implementation of the Inflation Reduction Act (PL 117-169), and implementation of Executive Order 14273, Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients. Issues related to FDA regulation of pharmaceuticals.
Client expense: — · Firm income: $60,000
Matched citations: H.R. 1227
Issues related to pain management, including S.475/H.R. 1227 - Alternatives to PAIN Act. Issues related to prescription drug value, including implementation of the Inflation Reduction Act (PL 117-169), and implementation of Executive Order 14273, Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients. Issues related to FDA regulation of pharmaceuticals.
Client expense: — · Firm income: $60,000
Matched citations: S.475
H.R. 1227/S. 475, Alternatives to PAIN Act and issues related to payment policies for non-opioid pain medication; Issues related to Most Favored Nation (MFN) drug pricing proposal; Issues related to Senate Finance Dear Colleague process; Kidney care issues; FY27 LHHS and Mil-Con appropriations report language
Client expense: — · Firm income: $60,000
Matched citations: H.R. 1227
H.R. 1227/S. 475, Alternatives to PAIN Act and issues related to payment policies for non-opioid pain medication; Issues related to Most Favored Nation (MFN) drug pricing proposal; Issues related to Senate Finance Dear Colleague process; Kidney care issues; FY27 LHHS and Mil-Con appropriations report language
Client expense: — · Firm income: $60,000
Matched citations: S. 475
Patient access to rare and orphan disease therapeutics; FDA regulatory pathways for pharmaceuticals; Awareness of Cystic Fibrosis and Sickle Cell Disease; Education about non-opioid pain therapies and Medicare beneficiary access to non-opioid medicines; HR 1227 and S. 375
Client expense: — · Firm income: $50,000
Matched citations: HR 1227
Transition-to-Success Mentoring Act
2026 · third_quarter · Firm: STANTON PARK GROUP
Patient access to rare and orphan disease therapeutics; FDA regulatory pathways for pharmaceuticals; Awareness of Cystic Fibrosis and Sickle Cell Disease; Education about non-opioid pain therapies and Medicare beneficiary access to non-opioid medicines; HR 1227 and S. 375
Client expense: — · Firm income: $50,000
Matched citations: S. 375
Issues related to Kidney health, HR 1227 Alternatives to Pain Act.
Client expense: — · Firm income: $50,000
Matched citations: HR 1227
Alternatives to PAIN Act
2026 · third_quarter · Firm: VERTEX PHARMACEUTICALS INCORPORATED
Unmet medical need in acute pain; H.R. 1227/S. 475 - The Alternatives to PAIN Act; Implementation of Public Law No: 117-328 sec. 4135 NO PAIN Act; Medically necessary fertility treatments for patients undergoing fully myeloablative conditioning; CMMI demo focusing on sickle cell disease; Drug Pricing Policies including Most Favored Nation policy proposals.
Client expense: $1,100,000 · Firm income: —
Matched citations: H.R. 1227
Cameron’s Law
2026 · third_quarter · Firm: VERTEX PHARMACEUTICALS INCORPORATED
Corporate tax reform; H.R. 1414 - Cameron's Law, Preservation of Orphan Drug Tax Credit.
Client expense: $1,100,000 · Firm income: —
Matched citations: H.R. 1414
New Era of Preventing End-Stage Kidney Disease Act
2026 · third_quarter · Firm: VERTEX PHARMACEUTICALS INCORPORATED
Federal policies impacting pharmaceutical development, approval, and reimbursement; Copay accumulators and maximizers, H.R. 6423/S. 864 - HELP Copays Act; Alternative Funding Programs; Unmet medical need in acute pain; Barriers to patient access of non-opioid pain medicines; General education about kidney disease, including APOL-1 and H.R. 1518 - New Era of Preventing End-Stage Kidney Disease; Cystic Fibrosis; Sickle cell disease; Innovations in Type 1 diabetes treatments.
Client expense: $1,100,000 · Firm income: —
Matched citations: H.R. 1518
HELP Copays Act
2026 · third_quarter · Firm: VERTEX PHARMACEUTICALS INCORPORATED
Federal policies impacting pharmaceutical development, approval, and reimbursement; Copay accumulators and maximizers, H.R. 6423/S. 864 - HELP Copays Act; Alternative Funding Programs; Unmet medical need in acute pain; Barriers to patient access of non-opioid pain medicines; General education about kidney disease, including APOL-1 and H.R. 1518 - New Era of Preventing End-Stage Kidney Disease; Cystic Fibrosis; Sickle cell disease; Innovations in Type 1 diabetes treatments.
Client expense: $1,100,000 · Firm income: —
Matched citations: H.R. 6423
Alternatives to PAIN Act
2026 · third_quarter · Firm: VERTEX PHARMACEUTICALS INCORPORATED
Unmet medical need in acute pain; H.R. 1227/S. 475 - The Alternatives to PAIN Act; Implementation of Public Law No: 117-328 sec. 4135 NO PAIN Act; Medically necessary fertility treatments for patients undergoing fully myeloablative conditioning; CMMI demo focusing on sickle cell disease; Drug Pricing Policies including Most Favored Nation policy proposals.
Client expense: $1,100,000 · Firm income: —
Matched citations: S. 475
Federal policies impacting pharmaceutical development, approval, and reimbursement; Copay accumulators and maximizers, H.R. 6423/S. 864 - HELP Copays Act; Alternative Funding Programs; Unmet medical need in acute pain; Barriers to patient access of non-opioid pain medicines; General education about kidney disease, including APOL-1 and H.R. 1518 - New Era of Preventing End-Stage Kidney Disease; Cystic Fibrosis; Sickle cell disease; Innovations in Type 1 diabetes treatments.
Client expense: $1,100,000 · Firm income: —
Matched citations: S. 864
Alternatives to PAIN Act
2026 · third_quarter · Firm: CROSSROADS STRATEGIES, LLC
General education about federal policies impacting pharmaceutical development, approval, and reimbursement. Education about non-opioid pain therapies.H.R.1227/S.475 Alternatives to Prevent Addiction in the Nation (Alternatives to PAIN) Act.
Client expense: — · Firm income: $50,000
Matched citations: H.R.1227
Alternatives to PAIN Act
2026 · third_quarter · Firm: CROSSROADS STRATEGIES, LLC
General education about federal policies impacting pharmaceutical development, approval, and reimbursement. Education about the importance of access to non-opioid pain therapies for Medicare beneficiaries. H.R.1227/S.475 Alternatives to Prevent Addiction in the Nation (Alternatives to PAIN) Act.
Client expense: — · Firm income: $50,000
Matched citations: H.R.1227
General education about federal policies impacting pharmaceutical development, approval, and reimbursement. Education about non-opioid pain therapies.H.R.1227/S.475 Alternatives to Prevent Addiction in the Nation (Alternatives to PAIN) Act.
Client expense: — · Firm income: $50,000
Matched citations: S.475
General education about federal policies impacting pharmaceutical development, approval, and reimbursement. Education about the importance of access to non-opioid pain therapies for Medicare beneficiaries. H.R.1227/S.475 Alternatives to Prevent Addiction in the Nation (Alternatives to PAIN) Act.
Client expense: — · Firm income: $50,000
Matched citations: S.475
Patient access to rare and orphan disease therapeutics; FDA regulatory pathways for pharmaceuticals; Awareness of Cystic Fibrosis and Sickle Cell Disease; Education about non-opioid pain therapies and Medicare beneficiary access to non-opioid medicines; HR 1227 and S. 375
Client expense: — · Firm income: $50,000
Matched citations: HR 1227
Transition-to-Success Mentoring Act
2026 · second_quarter · Firm: STANTON PARK GROUP
Patient access to rare and orphan disease therapeutics; FDA regulatory pathways for pharmaceuticals; Awareness of Cystic Fibrosis and Sickle Cell Disease; Education about non-opioid pain therapies and Medicare beneficiary access to non-opioid medicines; HR 1227 and S. 375
Client expense: — · Firm income: $50,000
Matched citations: S. 375
H.R. 1227/S. 475, Alternatives to PAIN Act and issues related to payment policies for non-opioid pain medication; Issues related to Most Favored Nation (MFN) drug pricing proposal; Issues related to Senate Finance Dear Colleague process; Kidney care issues; FY27 LHHS and Mil-Con appropriations report language
Client expense: — · Firm income: $60,000
Matched citations: H.R. 1227
H.R. 1227/S. 475, Alternatives to PAIN Act and issues related to payment policies for non-opioid pain medication; Issues related to Most Favored Nation (MFN) drug pricing proposal; Issues related to Senate Finance Dear Colleague process; Kidney care issues; FY27 LHHS and Mil-Con appropriations report language
Client expense: — · Firm income: $60,000
Matched citations: S. 475
Access to innovative non-opioid medicines; Alternatives to PAIN, H.R. 1227; Alternatives to PAIN, S. 475.
Client expense: — · Firm income: $50,000
Matched citations: H.R. 1227
Access to innovative non-opioid medicines; Alternatives to PAIN, H.R. 1227; Alternatives to PAIN, S. 475.
Client expense: — · Firm income: $50,000
Matched citations: S. 475
Source: Senate LDA